reference

Fearnhead H, Gul S. Using clinical drug resistance to kill cancer cells. Drug Target Review. 2017;3:12-14

Posted: 12 July 2017 | | No comments yet

References

  1. Pal C, Papp B, Lazar V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 2015;23:401-7.
  2. Guthrie R, Loebeck ME, Hillman MJ, Zgorzynski F. Tests for collateral sensitivity or cross resistance in bacterial mutants resistant to amethopterin or purine analogs. Cancer Res. 1958;18:319-34.
  3. Imamovic L, Sommer MO. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 2013;5: 204ra132.
  4. Kim S, Lieberman TD, Kishony R. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci USA. 2014;111: 14494-9.
  5. Gonzales PR, Pesesky MW, Bouley R, Ballard A, Biddy BA, Suckow MA, Wolter WR, Schroeder VA, Burnham CA, Mobashery S, Chang M, Dantas G. 2015. Synergistic, collaterally sensitive beta-lactam combinations suppress resistance in MRSA. Nat Chem Biol. 2015;11:855-61.
  6. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat. 2012; 15:98-105.
  7. Goldsborough AS, Handley MD, Dulcey AE, Pluchino KM, Kannan P, Brimacombe KR, Hall MD, Griffiths G, Gottesman MM. Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem. 2011;54:4987-97.
  8. Hall MD, Marshall TS, Kwit AD, Miller Jenkins LM, Dulcey AE, Madigan JP, Pluchino KM, Goldsborough AS, Brimacombe KR, Griffiths GL, Gottesman MM. Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin. J Biol Chem. 2014;289:21473-89.
  9. Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell. 2016;165:234-46.
  10. Evrard A, Cuq P, Ciccolini J, Vian, l. & cano, j. p. 1999. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer, 80, 1726-33.
  11. Evrard A, Cuq P Robert B, Vian L, Pelegrin A, Cano JP. 1999. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer. 1999;80:465-70.
  12. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV. 1998. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res, 4, 2371-6.
  13. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. 1999. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006-11.
  14. Baskin Y, Amirfallah A, Unal OU, Calibasi G, Oztop I. Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil: a case report. Am J Ther. 2015;22:e36-9.
  15. Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001;8:966-73.
  16. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-wei, DD, Lenz HJ, Leichman CG, leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322-7.
  17. Mochinaga K, Tsuchiya T, Nagasaki T, Arai J, Tominaga T, Yamasaki N, Matsumoto K, Miyazaki T, Nanashima A, Hayashi T, Tsukamoto K, Nagayasu T. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non–small-cell lung cancer using 5-fluorouracil. Clin Lung Cancer. 2014;15:136-144 e4.
  18. Fanciullino R, Evrard A, Cuq P, Giacometti S, Peillard L, Mercier C, Aubert C, Milano G, Ciccolini J. Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. Anticancer Drugs. 2006;17, 463-70.
  19. Tong Y, Liu-Chen X, Ercikan-Abali EA, Capiaux GM, Zhao SC, Banerjee D, Bertino, JR. Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem. 1998;273: 11611-8.
  20. Hughey CT, Barbour KW, Berger FG, Berger SH. Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. Mol Pharmacol. 1993;44:316-23.
  21. Sanguedolce R, Alessandro R, De Leo G, Gullotti L, Sanguedolce F, Vultaggio G, Diana G, Cirello B, Rausa L. Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study. Anticancer Res. 2000;20:4347-50.
  22. Saga Y, Suzuki M, Mizukami H, Kohno T, Takei Y, Fukushima M, Ozawa K. Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells. Int J Cancer. 2003;106:324-6.
  23. Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, Maxwell P, Harkin DP, Johnston PG. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res. 2001;7:3533-9.
  24. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 1995;49:1419-26.
  25. Clark JL, Berger SH, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep. 1987;71:261-5.
  26. Berger SH, Jenh CH, Johnson LF, Berger FG. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol. 1985;28:461-7.
  27. Jenh CH, Geyer PK, Baskin F, Johnson LF. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol Pharmacol. 1985;28:80-5.
  28. Shimizu T, Nakagawa Y, Takahashi N, Hashimoto S. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer. Clin Transl Oncol. 2016;18:107-12.
  29. Watson RG, Muhale F, Thorne LB, Yu J, O’Neil BH, Hoskins JM, Meyers,MO, Deal AM, Ibrahim JG, Hudson ML, Walko CM, Mcleod HL. & Auman, J. T. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer.2010;46:3358-64.
  30. Wang TL, Diaz LA Jr, Romans K, Bardelli A. Saha S. Galizia G. Choti M. Donehower R, Parmigiani G, Shih Ie M, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu, VE. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004;101;3089-94.
  31. Chu J and Dolnick BJ. Natural antisense (rTSalpha) RNA induces site-specific cleavage of thymidylate synthase mRNA. Biochim Biophys Acta. 2002;1587:183-93.
  32. De Angelis, PM, Svendsrud DH, Kravik KL, Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006;5:20.
  33. Wang W, Cassidy J, O’brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res. 2004b;64:8167-76.
  34. De Angelis, PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke T. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol. 2004;24:1279-88.
  35. Kang HC, Kim IJ, Park HW, Jang SG, Ahn SA, Yoon SN, Chang HJ, Yoo BC, Park JG. Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. Cancer Lett. 2007;247:40-7.
  36. Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Steger GG, Sedivy R, Mueller MW, Mader, RM. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004;112;200-12.
  37. Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Sedivy R, Steger GG, Muller MW, Mader RM. Gene expression profiling of colon cancer reveals a broad molecular repertoire in 5-fluorouracil resistance. Int J Clin Pharmacol Ther. 2003;41:624-5.
  38. Szoke D, Gyorffy A, Surowiak P, Tulassay Z, Dietel M, Gyorffy B. Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer. Onkologie. 2007;30:421-6.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Send this to a friend